Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BCC 2021 | Tackling residual disease in breast cancer

Lisa Carey, MD, FASCO, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, talks on attempts to tackle residual disease in patients with breast cancer. The presence of residual disease following therapy is predictive of poor outcomes. Several drugs are being studied in this setting including capecitabine, antibody-drug conjugates, and immune checkpoint inhibitors. This interview took place during the 17th St. Gallen International Breast Cancer Conference.


Prof. Carey reports institutional financial interests with the following commercial entities: Novartis, G1 Therapeutics, Genetech/Roche, Lilly, Innocrin, Seattle Genetics, Merck, Immunomedics.